Supriya Lifescience Ltd
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]
- Market Cap ₹ 5,383 Cr.
- Current Price ₹ 669
- High / Low ₹ 842 / 556
- Stock P/E 29.0
- Book Value ₹ 134
- Dividend Yield 0.15 %
- ROCE 27.5 %
- ROE 20.8 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 696 | 735 | |
| 166 | 191 | 213 | 213 | 218 | 316 | 332 | 394 | 436 | 471 | |
| Operating Profit | 17 | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 261 | 264 |
| OPM % | 9% | 10% | 23% | 32% | 44% | 40% | 28% | 31% | 37% | 36% |
| 7 | 9 | 8 | 11 | 5 | 8 | 9 | 11 | 10 | 11 | |
| Interest | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 | 2 |
| Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 20 | 26 |
| Profit before tax | 8 | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 248 | 247 |
| Tax % | 30% | 40% | 31% | 24% | 26% | 27% | 27% | 28% | 24% | |
| 6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 188 | 185 | |
| EPS in Rs | 3.87 | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 11.17 | 14.80 | 23.35 | 23.02 |
| Dividend Payout % | 0% | 0% | 0% | 20% | 3% | 3% | 5% | 5% | 4% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 10% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 7% |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 49% |
| 1 Year: | 4% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 17% |
| Last Year: | 21% |
Balance Sheet
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 981 | 1,066 |
| 140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 5 | 5 | |
| 55 | 60 | 69 | 105 | 105 | 92 | 98 | 101 | 110 | 116 | |
| Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,112 | 1,203 |
| 89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 453 | 458 | |
| CWIP | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 148 | 172 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 63 | 57 |
| 117 | 120 | 133 | 197 | 267 | 502 | 466 | 399 | 448 | 516 | |
| Total Assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,112 | 1,203 |
Cash Flows
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| 27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | 165 | |
| -27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | -152 | |
| -2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | -8 | |
| Net Cash Flow | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 | 4 |
Ratios
Figures in Rs. Crores
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 92 | 79 | 60 | 69 | 79 | 67 | 71 | 70 |
| Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 | 205 |
| Days Payable | 121 | 112 | 110 | 130 | 145 | 91 | 130 | 98 | 129 |
| Cash Conversion Cycle | 91 | 64 | 45 | 61 | 130 | 160 | 171 | 114 | 146 |
| Working Capital Days | -69 | -50 | -5 | -40 | 28 | 117 | 168 | 157 | 144 |
| ROCE % | 14% | 37% | 50% | 60% | 43% | 19% | 22% | 27% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
17 Feb - Transcript of the Earnings Call for the Unaudited Financial Results for quarter and nine months ended December 31, 2025, is enclosed herewith. Kindly take the …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
10 Feb - Audio of Feb 10, 2026 earnings call for quarter and nine months ended Dec 31, 2025 available on company website.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
10 Feb - Newspaper Publication of Unaudited Financial Results for the quarter and nine months ended December 31, 2025 is enclosed.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
10 Feb - Q3 FY26 revenue Rs206.44cr (11% YoY); PAT Rs49.68cr; EBITDA Rs72.08cr; capacity utilisation 76%.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
9 Feb - Investor Presentation for Results Earnings Call for Quarter and Nine Months ended on December 31, 2025 is enclosed herewith. Kindly take the same on record.
Annual reports
Concalls
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT REC
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT REC
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptAI SummaryPPT
-
Feb 2022TranscriptPPT
-
Jan 2022Transcript PPT
Niche Products Offerings[1]
Supriya Lifescience Ltd. has a niche product basket of 40+ APIs and is a global leader in Anti-histamines, anti-allergy, Vitamins, Anti-Asthmatics, & Anesthetics. They utilize a backward-integrated model for 15 products and possess the ability to handle complex chemistries and controlled substances.